This article is more than 5 years old. Information may no longer be current.
Anti-VEGF therapy effective in choroidal neovascularization with choroidal osteoma
Click Here to Manage Email Alerts
PHILADELPHIA — Choroidal neovascularization and retinal exudation in patients with choroidal osteoma can be regulated with anti-VEGF therapy, according to a study presented here.
Not only is anti-VEGF therapy efficacious in these patients, but it also helps preserve visual acuity, which is the ultimate goal in a benign tumor, M. Ali Khan, MD, said at the Wills Eye Institute Annual Conference.
M. Ali Khan
The retrospective observational series comprised eight eyes of eight patients with choroidal osteoma given a mean of nine intravitreal injections. Mean follow-up was 32.5 months.
Neovascularization was controlled in seven patients, and one patient had recurrence. All eight eyes achieved regression of CNV as an end result, with a mean gain of one line of vision, Khan said.
"The natural history of this tumor is to have poor vision at 10 years, less than 20/200," Khan said. "The mean was gaining one line of vision and the worst visual acuity at the end of this study was 20/60, so we thought they were doing pretty well [considering] the natural history of the tumor."
Disclosure: Khan has no relevant financial disclosures.